Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03490461|
Recruitment Status : Completed
First Posted : April 6, 2018
Last Update Posted : April 6, 2018
|Condition or disease||Intervention/treatment|
|Hepatocellular Carcinoma||Drug: Statin|
|Study Type :||Observational|
|Actual Enrollment :||350 participants|
|Official Title:||Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation|
|Actual Study Start Date :||November 22, 2017|
|Actual Primary Completion Date :||March 1, 2018|
|Actual Study Completion Date :||March 1, 2018|
Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
the administration of statins for less than 30 days after liver transplantation
- A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC. [ Time Frame: up to December, 2017 ]Usually, liver CT is performed at 1 week, 1 month, 6 months, and every year until 5 years after surgery. Afterwards, liver CT is performed at 2-year intervals. Measurement of blood tumor markers [AFP and prothrombin induced by vitamin K absence-II] is performed every month for 6 months after discharge from the hospital and every 3 months thereafter. Additional liver CT, liver magnetic resonance imaging, or positron emission tomography-CT is performed when elevated tumor markers or suspicious lesions were noted. A new lesion with radiographic features compatible with HCC is defined as recurrence of HCC based on the reports of specialist in radiology.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03490461
|Korea, Republic of|
|Division of Endocrinology and Metabolism Department of Internal Medicine, Yonsei University College of Medicine|
|Seoul, Korea, Republic of, 03722|